Anti-idiotype cancer vaccine TriAb - Titan
Alternative Names: Anti-idiotype monoclonal antibody vaccine (TriAb); Monoclonal antibody 11D10 anti-idiotype - Titan; TriAbLatest Information Update: 26 Aug 2004
At a glance
- Originator Titan Pharmaceuticals
- Developer Cancer and Leukemia Group B; Titan Pharmaceuticals
- Class Cancer vaccines; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 26 Aug 2004 Discontinued - Phase-II for Breast cancer in USA (unspecified route)
- 26 Aug 2004 Discontinued - Phase-II for Colorectal cancer in USA (unspecified route)
- 26 Aug 2004 Discontinued - Phase-II for Non-small cell lung cancer in USA (unspecified route)